|  |  | PIN | P | Tumors |
---|
Genotype | Animals No | 9cRA | Incidence | Frequency | Â | P | DO |
---|
p27+/+ | 18 | 0 | 11 | 0.16 ± 0.5 |  | 0 | 0 |
p27+/+ | 17 | + | 0 | 0 | 0 | 0 | 0 |
p27+/- | 16 | 0 | 60 | 1.5 ± 0.5* |  | 3 | 4 |
p27+/- | 15 | + | 44 | 1.1 ± 0.6 | 0.05 | 2 | 4 |
p27-/- | 15 | 0 | 70 | 2.0 ± 0.4* |  | 3 | 6 |
p27-/- | 15 | + | 53 | 1.4 ± 0.5 | 0.005 | 4 | 6 |
- Animals were treated with MNU, 30 mg/kg body weight at the age of 2 months and followed until sacrifice between 7-12 months of age. PIN were identified in DLP by cutting longitudinally through the urethral part of the prostate. H&E staining was used for identification of PIN. Stepwise, 4 μm thick paraffin sections at three separate tissue levels 30 μm apart were cut and the number of PIN per prostate determined. Incidence, percentage of animals with PIN per group; frequency, number of PIN per animal. PIN were determined in various groups without knowledge of the treatment protocol. (P), prostate; (DO), distant organs; *, significant difference (p < 0.01) in the multiplicity of PIN between p27+/- and p27-/- mice;